As of 2024-12-13, the Relative Valuation of Madrigal Pharmaceuticals Inc (MDGL) is (662.90) USD. This relative valuation is based on P/E multiples. With the latest stock price at 302.47 USD, the upside of Madrigal Pharmaceuticals Inc based on Relative Valuation is -319.2%.
The range of the Relative Valuation is (466.11) - (827.59) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 17.5x - 34.8x | 26.2x |
| Forward P/E multiples | 19.6x - 39.6x | 29.6x |
| Fair Price | (466.11) - (827.59) | (662.90) |
| Upside | -254.1% - -373.6% | -319.2% |
| Date | P/E |
| 2024-12-12 | -12.72 |
| 2024-12-11 | -12.89 |
| 2024-12-10 | -13.15 |
| 2024-12-09 | -13.39 |
| 2024-12-06 | -13.49 |
| 2024-12-05 | -13.16 |
| 2024-12-04 | -13.39 |
| 2024-12-03 | -13.51 |
| 2024-12-02 | -13.39 |
| 2024-11-29 | -13.80 |
| 2024-11-27 | -13.94 |
| 2024-11-26 | -14.16 |
| 2024-11-25 | -14.51 |
| 2024-11-22 | -14.61 |
| 2024-11-21 | -13.84 |
| 2024-11-20 | -13.33 |
| 2024-11-19 | -13.21 |
| 2024-11-18 | -12.76 |
| 2024-11-15 | -12.13 |
| 2024-11-14 | -12.73 |
| 2024-11-13 | -13.25 |
| 2024-11-12 | -14.26 |
| 2024-11-11 | -14.28 |
| 2024-11-08 | -14.75 |
| 2024-11-07 | -14.92 |
| 2024-11-06 | -14.22 |
| 2024-11-05 | -14.20 |
| 2024-11-04 | -13.93 |
| 2024-11-01 | -13.44 |
| 2024-10-31 | -10.91 |
| 2024-10-30 | -9.08 |
| 2024-10-29 | -9.16 |
| 2024-10-28 | -9.12 |
| 2024-10-25 | -8.86 |
| 2024-10-24 | -8.54 |
| 2024-10-23 | -8.51 |
| 2024-10-22 | -8.56 |
| 2024-10-21 | -8.78 |
| 2024-10-18 | -9.02 |
| 2024-10-17 | -8.85 |
| 2024-10-16 | -9.07 |
| 2024-10-15 | -9.09 |
| 2024-10-14 | -9.06 |
| 2024-10-11 | -9.00 |
| 2024-10-10 | -8.85 |
| 2024-10-09 | -8.87 |
| 2024-10-08 | -9.12 |
| 2024-10-07 | -9.03 |
| 2024-10-04 | -8.76 |
| 2024-10-03 | -8.69 |